Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E59.86 EPS (ttm)0.49 Insider Own0.90% Shs Outstand301.94M Perf Week-0.91%
Market Cap8.91B Forward P/E37.98 EPS next Y0.78 Insider Trans-25.15% Shs Float285.66M Perf Month-3.18%
Income150.90M PEG1.30 EPS next Q0.12 Inst Own82.10% Short Float5.65% Perf Quarter13.28%
Sales410.00M P/S21.73 EPS this Y63.70% Inst Trans-0.94% Short Ratio6.21 Perf Half Y10.15%
Book/sh0.81 P/B36.43 EPS next Y57.61% ROA26.10% Target Price34.00 Perf Year35.74%
Cash/sh1.22 P/C24.27 EPS next 5Y46.00% ROE101.20% 52W Range18.03 - 32.50 Perf YTD-2.93%
Dividend- P/FCF47.07 EPS past 5Y-19.90% ROI-15.10% 52W High-9.20% Beta1.82
Dividend %- Quick Ratio4.30 Sales past 5Y-7.90% Gross Margin96.90% 52W Low63.67% ATR1.23
Employees287 Current Ratio4.30 Sales Q/Q145.20% Oper. Margin39.30% RSI (14)51.26 Volatility2.69% 4.28%
OptionableYes Debt/Eq0.00 EPS Q/Q690.80% Profit Margin36.80% Rel Volume0.73 Prev Close29.10
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 AMC Payout0.00% Avg Volume2.60M Price29.51
Recom2.30 SMA200.02% SMA500.90% SMA20013.09% Volume1,898,425 Change1.41%
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Feb-23-18 09:19AM  Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost Zacks
08:55AM  Corcept's (CORT) Earnings and Sales Meet Estimates in Q4 Zacks
Feb-22-18 08:20AM  Todays Research Reports on Trending Tickers: AVEO Pharmaceuticals and Exelixis ACCESSWIRE
Feb-21-18 08:52AM  Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again? Zacks
Feb-20-18 08:27AM  Novartis Psoriasis Drug Cosentyx Positive in SCALP Study Zacks
Feb-19-18 10:04AM  AbbVie Presents New Data on Upadacitinib for Crohn's Disease Zacks
08:43AM  Celgene Reports Positive Data on Dermatology Drug Otezla Zacks
Feb-16-18 10:16AM  Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat Zacks
08:53AM  Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion Zacks
06:08AM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb Motley Fool
Feb-15-18 03:01PM  Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates Zacks
08:02AM  Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva Zacks
Feb-14-18 05:55PM  Roche's Rituxan Gets Priority Review for Label Expansion Zacks
05:48PM  AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda Zacks
04:05PM  Exelixis to Present at the RBC Capital Markets Global Healthcare Conference on February 21, 2018 Business Wire
01:43PM  Exelixis Reports Positive Data From Thyroid Carcinoma Trial Zacks
11:14AM  Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling Zacks
Feb-13-18 04:05PM  Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Business Wire
10:35AM  Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval Zacks
08:30AM  Todays Research Reports on Trending Tickers: Exelixis and 22nd Century Group ACCESSWIRE
08:16AM  Intercept Starts OCA Trial for NASH Patients With Cirrhosis Zacks
Feb-09-18 11:35AM  FDA Okays J&J's Prostate Cancer Drug in First-Line Setting Zacks
Feb-08-18 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018 Business Wire -7.13%
11:26AM  Theravance, J&J Ink Deal for Inflammatory Intestinal Drug Zacks
09:49AM  Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down Zacks
Feb-07-18 08:14AM  Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural Zacks
08:00AM  Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors Business Wire
Feb-06-18 04:05PM  Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 14 Business Wire
01:09PM  5 Biotech Stocks Set to Trump Estimates This Earnings Season Zacks
10:19AM  Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study Zacks
10:10AM  Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study Zacks
10:00AM  Pfizer Files for Xtandi in Early Stage Prostate Cancer Zacks
09:23AM  5 of the Best Efficient Stocks for Your Portfolio Zacks
Feb-05-18 07:10PM  Cramer's lightning round: Tableau Software is exactly the... CNBC Videos -5.82%
08:49AM  Billionaire Fund Managers Are Bullish On These Biotech Stocks Insider Monkey
Feb-03-18 09:20AM  Top 5 Biotech Stocks for 2018 Investopedia
Feb-02-18 10:00AM  Puma, CANbridge Team Up to Commercialize Nerlynx in China Zacks
09:30AM  Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review Zacks
08:16AM  Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings? Zacks
Feb-01-18 09:50AM  Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa Zacks
07:50AM  Report: Developing Opportunities within Omega Flex, Sun, First Citizens BancShares, Zynga, Infinera, and Exelixis Future Expectations, Projections Moving into 2018 GlobeNewswire
Jan-31-18 09:44AM  Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label Zacks
09:17AM  Puma & Medison Team Up to Commercialize Nerlynx in Israel Zacks
Jan-30-18 11:14AM  Theravance's NDA for COPD Candidate Gets FDA Acceptance Zacks
09:50AM  Roche Gets Breakthrough Therapy Designation For ASD Drug Zacks
Jan-29-18 04:24PM  5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
10:22AM  Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion Zacks
09:51AM  Quality Systems (QSII) Q3 Earnings in Line, Revenues Beat Zacks
Jan-25-18 10:30AM  Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y Zacks
10:29AM  Shire Gets FDA Nod for Cinryze Tech Transfer to New Site Zacks
Jan-24-18 03:22PM  EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down Zacks
07:02AM  The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ Zacks
Jan-23-18 04:37PM  Novartis Announces Positive Results on Migraine Candidate Zacks
10:45AM  Anthera's Sollpura Strong on Positive Futility in Phase III Zacks
09:44AM  Seattle Genetics' Adcetris Gets EU Nod for Label Expansion Zacks
09:42AM  Regeneron's Dupixent Receives MHLW Nod for Label Expansion Zacks
09:26AM  BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall Zacks
08:57AM  Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks Zacks
Jan-22-18 10:22AM  Bristol-Myers (BMY) Reports Data from CheckMate-142 Study Zacks +5.14%
Jan-20-18 10:55AM  Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Business Wire
Jan-19-18 10:59AM  Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year Zacks
10:23AM  Cancer Space Update: Label Expansions, Data Readouts in Focus Zacks
08:46AM  BeiGene (BGNE) Surges: Stock Moves 12.6% Higher Zacks
Jan-18-18 10:04AM  BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa Zacks
Jan-17-18 04:19PM  Why This Biotech Stock Is Diving Despite In-Line Liver Cancer Results Investor's Business Daily -7.28%
10:48AM  Merck Strong on Confirmatory Phase III Lung Cancer Study Zacks
09:36AM  Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It? Zacks
08:06AM  Exelixis, Ipsen Report Positive Results on Lead Cancer Drug Zacks
Jan-16-18 05:33PM  Exelixis, Ipsen report positive cancer-study results MarketWatch
05:01PM  Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma Business Wire
10:45AM  Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins? Market Realist
10:12AM  Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018? Zacks
09:15AM  Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance Market Realist
08:35AM  Novartis (NVS) Announces Acceptance of Humira BLA by the FDA Zacks
07:40AM  Analyst Recommendations for Vertex Pharmaceuticals in January Market Realist
Jan-15-18 08:24AM  Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion Zacks
07:37AM  Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead? Zacks
06:53AM  Roche MS Drug Ocrevus Gets Marketing Authorization in Europe Zacks
Jan-12-18 12:46PM  Aradigm's Bronchiectasis Candidate Has Negative FDA Vote Zacks
10:05AM  Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock? Zacks
09:16AM  The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex Zacks
09:05AM  Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod Zacks
08:04AM  Endo (ENDP) Gets Subpoena From Florida for Opioid Misuse Zacks
Jan-11-18 10:19AM  Can Biotech Keep Last Year's Momentum Alive in 2018? Zacks
09:46AM  Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU Zacks
08:01AM  Why is Novo Nordisk Stock Up More Than 50% in Past Year? Zacks
12:02AM  How Do Analysts See Exelixis Inc (NASDAQ:EXEL) Performing Over The Next Few Years? Simply Wall St.
Jan-10-18 10:33AM  4 Reasons Exelixis, Inc. More Than Doubled in 2017 Motley Fool
09:00AM  Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home Zacks
09:00AM  Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up Zacks
Jan-09-18 05:04PM  Emergent Down on '18 View, Posts Preliminary '17 Results Zacks
04:35PM  Acorda's Shares Down on Disappointing Ampyra View for 2018 Zacks
09:58AM  Novo Nordisk Confirms Bid for Ablynx But Faces Rejection Zacks
08:48AM  Agenus Inc., (AGEN) Jumps: Stock Rises 11.4% Zacks
08:00AM  Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Business Wire
Jan-08-18 03:42PM  Amgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma Zacks -7.34%
08:54AM  Alnylam, Sanofi Announce Restructuring Deal for RNAi Products Zacks
08:49AM  The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines Zacks
08:00AM  Exelixis and StemSynergy Enter into Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies Business Wire
Jan-05-18 04:25PM  4 Biotech Stocks to Watch in the New Year Zacks
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garber Alan MDirectorJan 09Option Exercise7.9711,50091,65572,829Jan 10 07:27 PM
Garber Alan MDirectorJan 09Sale30.0011,500345,00061,329Jan 10 07:27 PM
Garber Alan MDirectorJan 08Option Exercise7.973,50027,89564,829Jan 10 07:27 PM
Garber Alan MDirectorJan 08Sale31.293,500109,51561,329Jan 10 07:27 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Option Exercise9.9133,334330,340216,339Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 28Option Exercise1.9025,00047,500292,946Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 28Sale24.3225,000608,000267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Sale23.7433,334791,349183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 27Option Exercise1.902,3024,374270,248Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 27Sale23.902,30255,018267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Sale23.9433,333797,992183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Sale23.6833,333789,325183,005Sep 28 07:45 PM
PAPADOPOULOS STELIOSDirectorSep 22Sale25.4010,000254,0000Sep 22 07:07 PM
PAPADOPOULOS STELIOSDirectorSep 19Sale27.63127,7903,530,8381,034,314Sep 20 06:48 PM
PAPADOPOULOS STELIOSDirectorSep 18Sale27.7672,2102,004,5501,162,104Sep 20 06:48 PM
MORRISSEY MICHAELPresident and CEOSep 14Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialSep 14Sale27.2160,6401,650,01441,553Sep 15 06:43 PM
MORRISSEY MICHAELPresident and CEOSep 14Sale27.08100,0002,708,00060,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 13Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
WILLSEY LANCEDirectorSep 13Sale26.9750,0001,348,500468,273Sep 14 07:18 PM
MORRISSEY MICHAELPresident and CEOSep 13Sale27.04100,0002,704,00060,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 12Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Senner Christopher J.EVP and CFOSep 12Option Exercise3.66100,000366,000202,759Sep 14 07:17 PM
WILLSEY LANCEDirectorSep 12Sale26.7950,0001,339,500518,273Sep 14 07:18 PM
Senner Christopher J.EVP and CFOSep 12Sale26.79100,0002,679,000102,759Sep 14 07:17 PM
MORRISSEY MICHAELPresident and CEOSep 12Sale26.59100,0002,659,00060,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialMay 30Sale18.465,00092,300102,193Jun 01 07:09 PM
FELDBAUM CARL BDirectorMay 15Option Exercise8.7519,000166,19067,721May 16 09:13 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 15Option Exercise5.0412,50163,005183,005May 16 09:12 PM
FELDBAUM CARL BDirectorMay 15Sale21.5832,988711,83134,733May 16 09:13 PM
MORRISSEY MICHAELPresident and CEOMay 10Option Exercise1.86100,000185,910160,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 10Sale22.07100,0002,207,00060,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Option Exercise1.90100,000190,000111,214May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Sale21.69100,0002,168,70660,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Option Exercise1.9011,30021,47071,300May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Sale21.8111,300246,45360,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 05Option Exercise1.90100,000190,000149,555May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 05Sale21.85100,0002,184,70260,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Option Exercise1.9059,149112,383119,149May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Sale22.1759,1491,311,33360,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Option Exercise1.90100,000190,000129,427May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Sale22.67100,0002,266,80360,000May 05 06:53 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Option Exercise9.9189,910891,008260,414May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Sale23.0189,9102,068,519170,504May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOApr 17Option Exercise9.9110,09099,992168,143Apr 18 07:57 PM
MARCHESI VINCENT TDirectorApr 03Option Exercise10.5310,000105,300130,070Apr 04 08:00 PM
MARCHESI VINCENT TDirectorApr 03Sale21.3010,000213,000120,070Apr 04 08:00 PM
WYSZOMIERSKI JACK LDirectorMar 31Option Exercise10.5310,000105,30078,110Mar 31 06:35 PM
WYSZOMIERSKI JACK LDirectorMar 31Sale21.575,150111,08672,960Mar 31 06:35 PM
COHEN CHARLESDirectorMar 27Option Exercise10.5310,000105,300248,180Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 27Sale21.026,884144,702267,946Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 22Option Exercise1.7055,00093,500301,617Mar 24 07:41 PM
Hessekiel JeffreyEVP and General CounselMar 22Sale20.5423,787488,585277,830Mar 24 07:41 PM
PAPADOPOULOS STELIOSDirectorMar 20Option Exercise10.5310,000105,3001,238,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Option Exercise10.5310,000105,30058,721Mar 21 07:29 PM
FELDBAUM CARL BDirectorMar 20Sale21.7710,000217,70048,721Mar 21 07:29 PM
PAPADOPOULOS STELIOSDirectorMar 20Sale21.6610,000216,6001,228,471Mar 21 07:28 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Option Exercise6.2050,007310,179208,060Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Option Exercise10.5310,000105,300578,273Mar 17 07:52 PM
WILLSEY LANCEDirectorMar 15Sale22.8610,000228,600568,273Mar 17 07:52 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Sale22.5350,0071,126,658158,053Mar 17 07:51 PM
COHEN CHARLESDirectorMar 13Sale21.8210,000218,200238,180Mar 14 08:12 PM
MARCHESI VINCENT TDirectorMar 10Option Exercise3.1340,000125,200160,070Mar 10 07:37 PM
MARCHESI VINCENT TDirectorMar 10Sale21.9840,000879,200120,070Mar 10 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 06Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 06Sale22.61100,0002,261,00060,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 03Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Option Exercise7.27100,000727,000346,617Mar 07 08:00 PM
Senner Christopher J.EVP and CFOMar 03Sale22.8011,000250,800100,398Mar 03 08:20 PM
Hessekiel JeffreyEVP and General CounselMar 03Sale23.04100,0002,303,678246,617Mar 07 08:00 PM
MORRISSEY MICHAELPresident and CEOMar 03Sale22.83100,0002,283,00060,000Mar 07 07:56 PM
Haley Patrick J.Sr. Vice President, CommercialMar 03Sale23.042,50057,600107,193Mar 07 07:45 PM
POSTE GEORGEDirectorMar 02Option Exercise4.5167,400303,660144,955Mar 03 08:17 PM
POSTE GEORGEDirectorMar 02Sale22.5867,4001,521,89277,555Mar 03 08:17 PM
POSTE GEORGEDirectorMar 01Option Exercise10.538,85093,19186,405Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise7.3645,000331,350118,600Mar 03 08:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1945,000998,55073,600Mar 03 08:18 PM
POSTE GEORGEDirectorMar 01Sale22.188,850196,29377,555Mar 03 08:17 PM